AC Immune (NASDAQ:ACIU) Shares Cross Below 50 Day Moving Average – Should You Sell?

AC Immune (NASDAQ:ACIU)’s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.39 and traded as low as $2.22. AC Immune shares last traded at $2.27, with a volume of 106,019 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ACIU. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Monday, May 4th. Weiss Ratings downgraded shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Finally, HC Wainwright reissued a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AC Immune currently has a consensus rating of “Hold” and a consensus price target of $7.50.

AC Immune Stock Performance

The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. The stock’s 50-day moving average is $2.39 and its 200 day moving average is $2.79. The firm has a market cap of $231.02 million, a P/E ratio of -2.77 and a beta of 1.59.

Insider Activity

In other news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the sale, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On AC Immune

A number of hedge funds and other institutional investors have recently made changes to their positions in ACIU. Acadian Asset Management LLC raised its stake in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares during the period. Dimensional Fund Advisors LP increased its position in shares of AC Immune by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after purchasing an additional 36,353 shares during the last quarter. Marshall Wace LLP acquired a new position in AC Immune during the fourth quarter worth $586,000. Susquehanna International Group LLP bought a new stake in shares of AC Immune in the 3rd quarter valued at about $63,000. Finally, Goldman Sachs Group Inc. raised its stake in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.